FDA-approved

Digestive & weight

Semaglutide

Evidence

FDA approved

Class

GLP-1 receptor agonist

/

Semaglutide

KEY TAKEAWAY

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. In a large trial of adults with obesity, people taking 2.4 mg weekly lost about 15% of their body weight over 68 weeks, compared with about 2% on placebo.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A long-acting copy of the gut hormone GLP-1

Approved for

Type 2 diabetes, chronic weight management and cardiovascular risk reduction in selected adults

Key fact

Lowered body weight by roughly 15% in a 68-week trial

Route

Weekly injection or daily tablet

Evidence strength

FDA approved

What it is

What it is

Semaglutide is a modified version of the gut hormone GLP-1, engineered to last about a week in the body. It is sold under brand names including Ozempic, Wegovy and Rybelsus.

How it works

How it works

It activates GLP-1 receptors in the pancreas and brain. That raises insulin release after meals, slows stomach emptying and dampens appetite signals, so most people eat less without feeling as hungry.

Regulatory status

Regulatory status

The FDA approved semaglutide for type 2 diabetes in 2017 and for chronic weight management in 2021. Approval covers the branded products, not unapproved compounded copies.

What it is used for

What it is used for

Blood sugar control in type 2 diabetes, long-term weight management in adults with obesity or overweight plus a related condition, and lowering cardiovascular risk in selected patients.

Side effects and risks

Side effects and risks

Nausea, vomiting, diarrhea and constipation are the most common effects, especially as the dose goes up. Gallbladder problems and pancreatitis are less common. The label carries a boxed warning about thyroid C-cell tumors seen in rodents.

Citations

Citations

Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo